

# Q2/6M 2025/26 Results Presentation

May 12, 2026



thyssenkrupp  
nucera

# With you today



Dr. Werner Ponikwar (CEO)



Dr. Stefan Hahn (CFO)



Klaus Ohlig (CTO)

# Disclaimer

This presentation has been prepared by thyssenkrupp nucera AG & Co. KGaA (“thyssenkrupp nucera”) and comprises the written materials/slides for a presentation concerning thyssenkrupp nucera. By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions.

This presentation is for information purposes only and the information contained herein (unless otherwise indicated) has been provided by thyssenkrupp nucera. It does not constitute an offer to sell or the solicitation, inducement or an offer to buy shares in thyssenkrupp nucera or any other securities. Further, it does not constitute a recommendation by thyssenkrupp nucera or any other party to sell or buy shares in thyssenkrupp nucera or any other securities and should not be treated as giving investment, legal, accounting, regulatory, taxation or other advice. This presentation has been prepared without reference to any particular investment objectives, financial situation, taxation position and particular needs. In case of any doubt in relation to these matters, you should consult your stockbroker, bank manager, legal adviser, accountant, taxation adviser or other independent financial adviser.

The information contained in this presentation has not been independently verified, and no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information contained herein and no reliance should be placed on it. To the extent permitted by applicable law, none of thyssenkrupp nucera or any of its affiliates, advisers, connected persons or any other person accept any liability for any loss howsoever arising (in negligence or otherwise), directly or indirectly, from this presentation or its contents or otherwise arising in connection with this presentation. No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein.

This presentation contains forward-looking statements that are subject to risks and uncertainties. Statements contained herein that are not statements of historical fact may be deemed to be forward-looking information. When we use words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “estimate,” “may” or similar expressions, we are making forward-looking statements. You should not rely on forward-looking statements because they are subject to a number of assumptions concerning future events, and are subject to a number of uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from those indicated.

Any assumptions, views or opinions (including statements, projections, forecasts or other forward-looking statements) contained in this presentation represent the assumptions, views or opinions of thyssenkrupp nucera as of the date indicated and are subject to change without notice. Thyssenkrupp nucera neither intends, nor assumes any obligation, unless required by law, to update or revise these assumptions, views or opinions in light of developments which differ from those anticipated. All information not separately sourced is from internal company data and estimates. Any data relating to past performance contained herein is no indication as to future performance. The information in this presentation is not intended to predict actual results, and no assurances are given with respect thereto.

This presentation contains certain supplemental financial or operative measures that are not calculated in accordance with IFRS and are therefore considered as non-IFRS measures. We believe that such non-IFRS measures used, when considered in conjunction with (but not in lieu of) other measures that are computed in accordance with IFRS, enhance the understanding of our business, results of operations, financial position or cash flow. There are, however, material limitations associated with the use of non-IFRS measures including (without limitation) the limitations inherent in the determination of relevant adjustments. The non-IFRS measures used by us may differ from, and not be comparable to, similarly titled measures used by other companies.

All numbers shown are as reported, unless otherwise stated. All amounts are stated in million euros (mn €) unless otherwise indicated. Amounts below 0.5mn € are rounded and reported as 0. Rounding differences may occur.

# 1. Business update



thyssenkrupp  
NUCERA

# Q2 in a nutshell



**New commercial momentum in green hydrogen** marked by the signed contract with Moeve for a 300 MW project in Spain, and the awarded FEED study for a 260 MW project with Juno Joule in India



**Highest order intake since IPO and growing order backlog** driven by large new build orders in gH2 and CA segments



**Chlor-Alkali project execution well on track** – Unipar project in Brazil started up, 100% delivery completion for US OxyChem plant



**Adjusted FY 25/26 outlook<sup>1</sup> confirmed** after sales and EBIT were substantially impacted by higher gH2 project costs in Q2

<sup>1</sup> Outlook adjustments communicated per ad-hoc releases on March 17 and 18, 2026.

**gH<sub>2</sub> projects  
under execution  
~3.5 GW**

**Order intake  
316mn €**

**Total order backlog  
732mn €**

# New project wins demonstrate that gH2 market is visibly maturing

**moeve**



## 300 MW contract signed with Moeve

thyssenkrupp nucera will supply electrolyzers with a total capacity of 300 MW for first phase of the “Andalusian Green Hydrogen Valley”

Plant’s green hydrogen will enable renewable fuels for road, maritime, and aviation customers

Annual production capacity of ~45,000 tons of green hydrogen, avoiding about 250,000 tonnes of CO2 annually

## 260 MW FEED study with Juno Joule in India

thyssenkrupp nucera has been awarded a Front-End Engineering and Design (FEED) study for a 260 MW green hydrogen project in India

Developing a concept for the seamless integration of Alkaline Water Electrolysis into the plant infrastructure; project will be designed to produce green ammonia

EPF contract with a final investment decision targeted in FY 2026/27

New projects underpin trust in our technology and underscore positive developments in the maturing gH2 market

# Services will unlock long-term value beyond gH2 equipment sales

New Build




**~3.5 GW** of electrolyzers under execution create gH2 service sales potential of **>2bn €** over 25 years<sup>1</sup> based on long-term service agreements

Lifetime Service Offering



Training




Spare Parts



Digital Services



Refurbishment



Field Services



Predictive Maintenance



Value of our 360° Life Cycle Service Portfolio

- ✓ Top tier and LCOH-optimized service lifecycle management
- ✓ Electrolyzer operates at peak efficiency while minimizing operational risk
- ✓ Maximized availability and reduced OPEX

<sup>1</sup> Sales potential is based on reference from observations in the chlor-alkali business and on the already contracted gH2 projects. Future sales potential is subject to change depending on the completion of current and/or gain of further projects in the gH2 business.

# Resilient Chlor-Alkali business with execution reliability

## Sales pipeline



### New build order for large scale CA plant in the Middle East

- New contract signed to supply electrolyzers for large-scale Chlor-Alkali plant in the Middle East
- Order volume in the high double-digit million-euro range in Q2 2025/26, setting a record for thyssenkrupp nucera



### Service business orders above prior year's level

- Growing demand for services, particularly in China, the US and Europe

## Project execution

### Unipar Brazil

- All six BM electrolyzers in operation



### OxyChem US

- Delivery of entire equipment completed, shipments of spare parts also delivered



### AGC Vinythai Thailand

- Commercial operations of e-BiTAC electrolyzers started after successful capacity expansion



### TGV SRAACL

- Elements reached site
- Expected commissioning in calendar year 2026



Further potential for service & new build orders in the current fiscal year 2025/26

~3.5 GW of gH2 projects under execution



Final electrolyzer module installed at Stegra's gH2 plant in Boden, Sweden

### Stegra

- Installation of all 37 electrolyzer modules completed
- Moving into the next phases of pre-commissioning and commissioning


### NEOM

- Project continues to make progress
- Activities not impacted by recent events in the Middle East

### Shell

- Commissioning set to take place in 2026 and ramp-up of operations in 2027

# Diversified green hydrogen pipeline provides future order upside



**~1.6 GW**

of FEED contracts under execution with near to mid-term conversion potential

-300 MW Moeve  
+ 260 MW Juno Joule  
vs. Feb '26

gH<sub>2</sub> project pipeline as of May 2026.  
 1. Substantial pipeline = Projects where we had first interactions with and that are being monitored closely; 2. Projects which already passed the pursue / non-pursue gate.

# Green hydrogen scale-up in Europe requires systematic market building instruments from politics

## Value contribution

- Decarbonization of industry and transport by turning renewables into transportable and storable molecules
- Support resilience and local value chains by reducing the EU's dependence on fossil energy
- Electricity grid integration helps to integrate renewables, reduce grid congestion and system costs

## Market building instruments

- Create bankable markets through demand-side instruments and a reliable infrastructure build-up
- Simplify and harmonize electrolyzer requirements to reduce cost and compliance complexity
- Support industrial scale-up with content requirements and continuous funding mechanisms

## Industry initiatives/memberships



Electrolysis technology is proven, industrial projects are executable, and FIDs are achievable – under the right regulatory, market, and infrastructure conditions the market will grow fast

# AWE module enhancements

✓ First of its kind AWE technology based on 50+ years of experience in the CA business brought to the market in 2021

✓ Technology upgrades for 160 delivered modules based on five years of learnings from engineering, construction sites as well as in test facilities prior to upcoming commissioning

✓ Newly developed IP, additional sensors and adjusted plant design to further enhance reliability and safety of our modules

➔ Commission and operate green hydrogen plans reliably for 20 to 30 years while minimizing operational risk

➔ Top tier and LCOH-optimized service lifecycle management with maximized availability and reduced OPEX




# Next generation of green hydrogen products under development to meet evolving customer demands

## Full scope plant solution

- Integrated and standardized **120 MW plug-and-play electrolyzer system**
- **Significant cost** per MW reduction targeted
- **Compression** of up to 35 bar
- Partial outdoor design

Illustrative example



## Pressurized AWE systems

- **New pressurized AWE systems** based on successful modularized design concept
- **Prototype successfully started up** in Denmark

## SOEC strategic review

- **Promising and efficient technology**, still with longer time to market
- Review of SOEC roadmap to **explore strategic options**

Key short-term priority: further improve Levelized Cost of Hydrogen based on reduced CAPEX and industry-leading OPEX


## 2. Update on Q2/6M 2025/26 financials




thyssenkrupp  
NUCERA

# Positive development in order intake and FCF following project wins, while one-time effects strongly impact sales and EBIT


Order intake  
(mn €)




EBIT  
(mn €)



Sales  
(mn €)




Free Cash Flow  
(mn €)



➤ Surge in order intake builds base for future sale growth and earnings and supports the company's ability to continuously finance itself – Second quarter strongly impacted by one-time increase in project costs in gH<sub>2</sub> segment

# Growing order intake and backlog driven by major new build projects

Order intake (mn €)



### Order intake Q2


- CA increase (+76%) largely driven by major new build order in Middle East
- gH2 increase marked by 300 MW new-build project with Moeve secured in March 2026

### Order intake 6M

- Order intake and backlog above FY 24/25 level
- gH2 increase driven by Moeve order, CA New Build business above PY
- Order backlog on group level increased to 732mn € (31 March 2026)

# Sales temporarily burdened in green hydrogen, FY guidance intact

Sales (mn €)



Reduced by ~50mn € due to one-time effects

### Sales Q2


- gH2 sales impacted by technical accounting-related effect in the percentage of completion due to higher project costs
- CA (-14% yoy) due to lower new build business; service sales remained on PY level

### Sales 6M

- gH2 sales mainly due to declining NEOM sales and Q2 technical accounting one-time effects
- CA sales (-25% yoy); higher order intake in 6M to translate into sales in coming quarters
- FY assumptions remain valid

# EBIT impacted by gH2 one-offs – CA posted strong margin in Q2

EBIT (mn €)



## EBIT Q2


- gH2 significantly impacted by one-off items, incl. higher expenses for module optimization measures and termination of US pilot project
- CA almost on PY level despite lower sales thanks to improved project mix

## EBIT 6M

- Group EBIT decline mainly driven by lower sales volume in both segments and higher costs for gH2 projects
- Development in line with FY guidance

# Solid operating performance overshadowed by one-time effects

Operating costs (mn €)



## COGS

- One-time effects weighing on margin in gH2 segment
- Gross margin increase in CA segment thanks to improved project mix

## SG&A

- Cost containment and restrictive hiring compensating for inflation and one-time effects
- Sequential improvement compared to H2 2024/25 and further reduction expected for H2

## R&D

- Increased R&D efforts as planned
- R&D expenses partially capitalized

# Cost containment program is underway to counteract sales slow down

## Measures

## Savings potential (FY 2026/27)

### Cost structure optimization

- Reduced use of external consulting and optimization of IT costs
- Hiring freeze and non-replacement of departing FTEs in high-cost countries
- Reduction of working time in German entity (~40 FTEs equivalent)
- Reduction of office space

**>25mn €**  
in annual savings  
(vs. FY 2024/25)

### Strategic measures

- Reduction of module yard capacity
- Streamlining of R&D & gH2 product activities with a focus on securing long-term competitiveness
- Focus on 'best-cost countries' for engineering, commissioning, supply chain and support functions

**>15mn €**  
in annual savings  
(vs. FY 2024/25)

# Net income and EPS negatively impacted by EBIT decrease

## EBIT to EPS (mn €)

	Q2 2024/25	Q2 2025/26
EBIT	-4	-65
Financial income /(expense), net	4	2
Income tax expense	-3	-1
Net income	-3	-64
Earnings per share (EPS) (€)	-0.03	-0.50

	6M 2024/25	6M 2025/26
EBIT	4	-69
Financial income /(expense), net	10	5
Income tax expense	-8	-2
Net income	6	-66
Earnings per share (EPS) (€)	0.05	-0.53

### EBIT to EPS Q2

- Financial result impacted by lower interest income resulting from lower interest rates
- Net income and EPS impacted by substantial EBIT decline


### EBIT to EPS 6M

- Positive financial income due to interest earned on cash position
- Income tax expenses declined
- Negative EPS driven by EBIT loss due to one-time effects


# The business remains self-funded, preserving strategic flexibility

## Cash flow & balance sheet (mn €)

### Free Cash Flow



### Net Financial Assets



### Free Cash Flow

- Positive Free Cash Flow
- Operating CF: Decline driven by lower earnings and a cash outflow from reduction of trade payables
- Investing CF: Investments contain capitalized R&D expenses; Investments largely related to module and stack development and SOEC

### Net Financial Assets

- Increase driven by higher Q2 FCF
- Underlines balance-sheet strength, sufficient headroom to balance cyclicality and ramp-up profile of gH2

# Adjusted outlook for FY 2025/26 confirmed

## thyssenkrupp nucera Group

### Order intake

**550 to 850mn €**

FY 2024/25: 348mn €

### Sales

**450 to 550mn €**

FY 2024/25: 845mn €

### EBIT

**-80 to -30mn €**

FY 2024/25: 2mn €

## thyssenkrupp nucera segments

### gH<sub>2</sub>

**Sales 120 to 170mn €**

FY 2024/25: 459mn €

**EBIT -125 to -90mn €**

FY 2024/25: -56mn €

### CA

**Sales 320 to 400mn €**





FY 2024/25: 386mn €

**EBIT 45 to 65mn €**

FY 2024/25: 58mn €

Note: Outlook adjustments communicated per ad-hoc releases on March 17 and 18, 2026.

# Key messages

-  Increasing positive momentum in green hydrogen; strong order intake improves near-term visibility
-  Chlor-Alkali business continues to provide stable profits, cash generation and execution reliability
-  Quarterly financial performance impacted by gH2 one-offs – However, high liquidity, cash discipline and cost saving measures offer downside protection
-  We are implementing our strategic agenda and expanding our range of products and services to meet and exceed customer demands in a dynamic market

# Questions & Answers



# Events & Financial Calendar



## Upcoming events

- May 21-22 [Virtual Retail Investor Days](#)
- May 27 dbAccess European Champions Conference (Frankfurt)
- June 8 Roadshow Rheinland
- June 9-10 Roadshow Paris, London
- June 25 DSW Aktienforum, Münster



## Financial calendar

- Aug 12 Q3/9M 2025/26
- Dec 16 Q4/FY 2025/26



## IR Contact

+49 231 229 724 347

[ir@thyssenkrupp-nucera.com](mailto:ir@thyssenkrupp-nucera.com)

[investors.thyssenkrupp-nucera.com](https://investors.thyssenkrupp-nucera.com)

## PR Contact

+49 174 161 86 24

[press@thyssenkrupp-nucera.com](mailto:press@thyssenkrupp-nucera.com)

# Appendix



thyssenkrupp  
**NUCERA**

# EBITDA

(in mn €)	Q2 2024/25	Q2 2025/26
<b>EBITDA</b>	<b>-2</b>	<b>-61</b>
<i>EBITDA margin (in %)</i>	<i>-2%</i>	<i>-</i>

(in mn €)	6M 2024/25	6M 2025/26
<b>EBITDA</b>	<b>9</b>	<b>-62</b>
<i>EBITDA margin (in %)</i>	<i>2%</i>	<i>-</i>

# External sales by region

(in mn €)	Q2 2024/25	Q2 2025/26	6M 2024/25	6M 2025/26
Europe	48	23	122	99
North America	24	5	54	23
South America	17	6	48	16
Asia / Pacific	5	5	11	20
Greater China	16	15	29	24
India	6	4	7	5
Middle East & Africa	101	-8	207	10
<b>Total</b>	<b>216</b>	<b>50</b>	<b>479</b>	<b>197</b>

The allocation of sales is based on the location of the construction site of each project.

# Group | Summary income statement Q2

(in mn €)	Q2 2024/25	Q2 2025/26
<b>Sales</b>	<b>216</b>	<b>50</b>
Cost of sales	-197	-87
<b>Gross profit</b>	<b>20</b>	<b>-37</b>
<i>% margin</i>	9%	-73%
R&D	-8	-10
SG&A	-19	-19
Other income /(expense), net	3	0
<b>EBIT</b>	<b>-4</b>	<b>-65</b>
<i>% margin</i>	-2%	-
Financial income /(expense), net	4	2
<b>Earnings before taxes</b>	<b>0</b>	<b>-63</b>
Income tax expense	-3	-1
<b>Net income</b>	<b>-3</b>	<b>-64</b>
<b>Earnings per share (EPS) (in €)</b>	<b>-0.03</b>	<b>-0.50</b>

# Group | Summary income statement 6M

(in mn €)	6M 2024/25	6M 2025/26
<b>Sales</b>	<b>479</b>	<b>197</b>
Cost of sales	-429	-209
<b>Gross profit</b>	<b>50</b>	<b>-12</b>
<i>% margin</i>	10%	-6%
R&D	-15	-18
SG&A	-37	-37
Other income /(expense), net	5	-2
<b>EBIT</b>	<b>4</b>	<b>-69</b>
<i>% margin</i>	1%	-
Financial income /(expense), net	10	5
<b>Earnings before taxes</b>	<b>14</b>	<b>-64</b>
Income tax expense	-8	-2
<b>Net income</b>	<b>6</b>	<b>-66</b>
<b>Earnings per share (EPS) (in €)</b>	<b>0.05</b>	<b>-0.53</b>

# Group | Summary balance sheet assets

(in mn €)	Sept 30, 2025	Mar 31, 2026
Property, plant and equipment	54	51
Goodwill	53	53
Intangible assets other than goodwill	28	36
Other non-current assets <sup>1</sup>	21	21
<b>Total non-current assets</b>	<b>156</b>	<b>161</b>
Inventories	179	157
Trade accounts receivable	50	64
Contract assets	36	26
Other financial assets	7	3
Cash and cash equivalents	684	684
Other current assets <sup>2</sup>	53	41
<b>Total current assets</b>	<b>1,009</b>	<b>974</b>
<b>Total assets</b>	<b>1,165</b>	<b>1,135</b>

1. Includes Other financial assets, Other non-financial assets and Deferred tax assets 2. Includes Other non-financial assets, Current income tax assets

# Group | Summary balance sheet equity and liabilities

(in mn €)	Sept 30, 2025	Mar 31, 2026
<b>Equity attributable to equity holders</b>	<b>753</b>	<b>687</b>
Accrued pension and similar obligations <sup>1</sup>	11	10
Other provisions	0	0
Deferred tax liabilities	0	0
Lease liabilities and other financial liabilities	24	24
<b>Total non-current liabilities</b>	<b>35</b>	<b>34</b>
Trade accounts payable	118	81
Contract liabilities	141	200
Lease liabilities and other financial liabilities	16	27
Other current liabilities <sup>2</sup>	103	106
<b>Total current liabilities</b>	<b>377</b>	<b>414</b>
<b>Total liabilities</b>	<b>413</b>	<b>448</b>
<b>Total equity and liabilities</b>	<b>1,165</b>	<b>1,135</b>

1. Includes Accrued pension and similar obligations and Provisions for other non-current employee benefits 2. Includes Provisions for current employee benefits, Other provisions, Current income tax liabilities and Other non-financial liabilities

# Group | Summary cash flow statement Q2

(in mn €)	Q2 2024/25	Q2 2025/26
<b>Net income</b>	<b>-3</b>	<b>-64</b>
Depreciation & amortisation	3	4
Change in NWC <sup>1</sup>	-31	55
Other operating cash flow <sup>2</sup>	31	19
<b>Cash flow from operating activities</b>	<b>0</b>	<b>14</b>
Expenditures for acquisitions	0	0
Capital expenditures	-6	-5
Proceeds from disposals	0	0
<b>Cash flow from investing activities</b>	<b>-6</b>	<b>-5</b>
Dividends paid to equity holders	0	0
Other financing cash flow	-1	-2
<b>Cash flow from financing activities</b>	<b>-1</b>	<b>-2</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>-6</b>	<b>6</b>
Effect of exchange rate changes	-1	1
<b>Cash and cash equivalents at end of year</b>	<b>702</b>	<b>684</b>

1. As per Cash Flow Statement and defined as: Changes in assets and liabilities net of non-cash effects in - Inventories, Trade accounts receivable, Contract assets, Trade accounts payable, Contract liabilities liabilities, net of non-cash effects in - Accrued pension and similar obligations and Other provisions, Other assets/liabilities not related to investing financing activities 2. Includes Deferred income taxes, net, Changes in assets and

# Group | Summary cash flow statement 6M

(in mn €)	6M 2024/25	6M 2025/26
<b>Net income</b>	<b>6</b>	<b>-66</b>
Depreciation & amortisation	5	7
Change in NWC <sup>1</sup>	-14	42
Other operating cash flow <sup>2</sup>	38	33
<b>Cash flow from operating activities</b>	<b>36</b>	<b>15</b>
Expenditures for acquisitions	0	0
Capital expenditures	-11	-12
Proceeds from disposals	0	0
<b>Cash flow from investing activities</b>	<b>-11</b>	<b>-12</b>
Dividends paid to equity holders	0	0
Other financing cash flow	-2	-3
<b>Cash flow from financing activities</b>	<b>-2</b>	<b>-3</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>22</b>	<b>0</b>
Effect of exchange rate changes	0	0
<b>Cash and cash equivalents at end of year</b>	<b>702</b>	<b>684</b>

1. As per Cash Flow Statement and defined as: Changes in assets and liabilities net of non-cash effects in - Inventories, Trade accounts receivable, Contract assets, Trade accounts payable, Contract liabilities liabilities, net of non-cash effects in - Accrued pension and similar obligations and Other provisions, Other assets/liabilities not related to investing financing activities 2. Includes Deferred income taxes, net, Changes in assets and



thyssenkrupp  
nucera